Skip to main content

Cost-efficient European adaptations of global health economic models

Experience with model adaptations in Austria, Belgium, France, Germany, Italy, Norway, Netherlands, Spain, Sweden, the UK

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

First UK Medtech strategy published

21 Feb 2023

On February 03, 2023, the first medical technology (Medtech) strategy in the UK was published. The new Medtech Directorate at the Department of Health and Social Care developed the strategy, which sets the government's ambition to accelerate access to innovative medical technologies. Building on the broader Life Sciences Vision, the document reviews the current UK Medtech landscape, outlines the vision for Medtech, and defines priority areas for action.

The vision focuses on three central objectives:

  • Right product, which must be safe for all, clinically effective, innovative, and sustainable;
  • Right price, which must be value for money, outcomes-focused, whole pathway cost, and quality data;
  • Right place, which must include access, availability, adoptions, and resilience.

Four priority areas to support the vision are resilience and continuity of supply, innovative and dynamic markets, enabling infrastructure, and specific market focuses. An implementation plan for the strategy will be published in early 2023, outlining the planned actions for each priority.

See more information here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.